

***C. difficile* control set, 10/14**

October 2014—SeraCare Life Sciences announced the launch of its Accurun 501 *C. difficile* Control, the company's first molecular control product targeting hospital-acquired infections.



Accurun 501 *C. difficile* Control is formulated for use with in vitro diagnostic tests that detect *C. difficile* DNA in human stool samples. Manufactured from cultured *Clostridium* bacteria of four different strains or species delivered in a set of four vials, the bacteria are inactivated and in a human synthetic stool matrix. The control is ready to use in assays that detect *C. difficile* DNA with any transport system.

[SeraCare Life Sciences](#), 800-676-1881